corest inhibitor tng260

Generic: CoREST Inhibitor TNG260

corest inhibitor tng260: developed by 1 company · 1 clinical trial tracked.

What we can confirm

1 tracked trial

Tango Therapeutics, Inc. (TNGX)

What it means

Source-backed records connect corest inhibitor tng260 to TNGX; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.

BioSniper AIPage evidence connected

Prepared research question

How could corest inhibitor tng260 → TNGX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Related indications

Non Small Cell Lung Cancer Lung Adenocarcinoma Lung Cancer

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)

Company	Phase	Indication
Tango Therapeutics, Inc. (TNGX) Non Small Cell Lung Cancer	Phase 1/Phase 2	Non Small Cell Lung Cancer

Clinical Trials (1)

A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination With an Anti-PD-1 Antibody In Patients With STK11 Mutated Advanced Solid Tumors

NCT05887492·Phase 1/Phase 2·TNGX

Active, not recruiting

Primary endpoint: Determine the MTD and RP2D(s) (Phase 1 only)

Interventionalopen126 targetStarted 2023-06Completion 2026-0913 sites · United StatesTango Therapeutics, Inc.

Frequently asked questions

Who is developing corest inhibitor tng260?

corest inhibitor tng260 is being developed by Tango Therapeutics, Inc..

How many clinical trials involve corest inhibitor tng260?

BioSniper tracks 1 clinical trial involving corest inhibitor tng260.